EX-16.1 2 f8k101819ex16-1_emmauslife.htm LETTER DATED OCTOBER 24, 2019 FROM SINGERLEWAK LLP TO THE SECURITIES AND EXCHANGE COMMISSION.

Exhibit 16.1

 

 

 

October 24, 2019

 

Securities and Exchange Commission

Washington, D.C. 20549

 

Commissioners:

 

We have read Emmaus Life Sciences, Inc.’s (formerly known as MYnd Analytics, Inc.) statements included under Item 4.01 of its Form 8-K filed on the October 24, 2919 and we agree with such statements concerning our firm.